The clinical study involved 16 patients with either colon, breast or lung cancers that had failed to respond to other treatments, and was made possible by advances in clustered regularly interspaced short palindromic repeats (CRISPR) technology, which is used as a means of gene editing and enables scientists to manipulate DNA.
The study tested the safety and feasibility of the technology, and despite the disease continuing to get worse in 11 patients, it was shown to stabilise in the other five…
